In this study, the prostate cancer (PCa) multistage murine model TRAMP and TRAMP-derived cells have been used to extensively characterize in vitro and in vivo the response and resistance to enzalutamide. The therapeutic profile as well as the resistance onset were characterized and a multiscale stochastic mathematical model was proposed to link the in vitro and in vivo evolution of PCa. The model showed that all therapeutic strategies that use enzalutamide result in the onset of resistance. The model also showed that combination therapies can delay the onset of resistance to enzalutamide, and in the best scenario, can eliminate the disease. These results set the basis for the exploitation of this "TRAMP-based platform" to test novel therapeutic approaches and build further mathematical models of combination therapies to treat PCa and CRPC.
FingerprintDive into the research topics of 'Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer'. Together they form a unique fingerprint.
Supplementary data for 'Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer'.
Cerasuolo, M. (Creator), Maccarinelli, F. (Creator), Coltrini, D. (Creator), Mokhtar, A. (Creator), Marolda, V. (Creator), Ghedini, G. C. (Creator), Rezzola, S. (Creator), Giacomini, A. (Creator), Triggiani, L. (Creator), Kostrzewa, M. (Creator), Verde, R. (Creator), Paris, D. (Creator), Melck, D. (Creator), Presta, M. (Creator), Ligresti, A. (Creator) & Ronca, R. (Creator), University of Portsmouth, 6 Feb 2020